The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
about
Overcoming the Underutilisation of Peritoneal DialysisDialysis: Biocompatible versus standard PD solutions--more balANZ data.Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ TrialThe impact of sub-clinical over-hydration on left ventricular mass in peritoneal dialysis patientsBalance about balANZ.Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomesDialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.Effects of a Statewide Protocol for the Management of Peritoneal Dialysis-Related Peritonitis on Microbial Profiles and Antimicrobial Susceptibilities: A Retrospective Five-Year Review.Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action.Is there such a thing as biocompatible peritoneal dialysis fluid?Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand.ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.Epidemiology, meta-analysis, and macro-economics.Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children.Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.The effect of biocompatible peritoneal dialysis solutions on neutrophil to lymphocyte ratio.Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.
P2860
Q26774019-6B02338F-DF68-45D9-823E-4AE105BE3071Q30572517-1431907D-10BB-497D-9E9D-BA756254B84AQ35106066-29068E9A-7755-4AE1-B730-9BD459E53F51Q35524711-F1C0E462-8512-4503-A2FA-EB38406CB8EAQ35791555-A8ED7076-66CE-41AA-948E-CAFF42D5C0BEQ36474255-52E29527-84FF-4AD3-AC21-CB3EB543ED4BQ37247002-E8649DD0-8573-4F6E-A684-5A87A6540A5EQ37485572-66C97834-2774-43CA-B067-3182CF3834C5Q38543677-9A9B36EE-EA9B-4568-8091-5306CA5734F4Q38710566-D8A52877-6CED-458B-B245-C29CE22F9C75Q38976940-FCDA44D6-C0F4-4035-A29F-F2038BA7E7BAQ39117321-194B1EAA-870D-47C9-A668-27A66AE5AD84Q40530036-0298A034-4E73-45A8-B2B3-9CFA3729C72CQ42104270-F152620C-82EB-4E59-8BA6-8D0403ABE8A1Q42797372-EC359B9A-E761-4A77-A472-7A21004451ABQ47128504-5D30262F-B771-470F-B98E-DC8891A5E6D1Q50091275-C8BB549D-F2C4-46B4-BDEB-11F73B2E8C7AQ53035844-C8902EA3-4B9C-4615-B341-81CD3B26BC26Q53329399-FF8AAB31-EE63-4E1F-8913-F9DB9F8ED866
P2860
The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@ast
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@en
type
label
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@ast
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@en
prefLabel
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@ast
The effects of biocompatible c ...... nd outcomes: the balANZ trial.
@en
P2093
P2860
P356
P1476
The effects of biocompatible c ...... and outcomes: the balANZ trial
@en
P2093
Bernard Jones
David Voss
Dwarakanathan Ranganathan
Fiona G Brown
John Schollum
Margaret Clarke
Marjorie W Y Foo
Michael G Suranyi
Neil Boudville
Robyn Langham
P2860
P304
P356
10.3747/PDI.2012.00052
P577
2012-09-01T00:00:00Z